drugset / Trial / NCT03761030

L-DOPA vs. Placebo for Depression and Psychomotor Slowing in Older Adults

NCT03761030

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Individuals with Late Life Depression (LLD) often have cognitive problems, particularly problems with memory, attention, and problem solving, all of which contribute to antidepressant non-response. Our group and others have shown that decreased thinking speed is the central cause of functional problems in patients with LLD. Similarly, decreased walking speed is associated with depression and carries additional risk for falls, hospitalization, and death. Available evidence suggests that declining functionality in the brain's dopamine system contributes to age-related cognitive and motor slowing. The central hypothesis of this study is that by enhancing dopamine functioning in the brain and improving cognitive and motor slowing, administration of carbidopa/levodopa (L-DOPA) will improve depressive symptoms in older adults.

Timeline

Start
2019-01-09
Primary completion
2021-09-08
Completion
2021-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 112.5 mg Oral
Subject Levodopa Small molecule 450 mg Oral